Polpharma Biologics announced a strategic corporate transformation, demerging into two independent companies to strengthen focus and accelerate growth across its core businesses.

• The biosimilars business will continue under the Polpharma Biologics brand, headquartered in Switzerland, advancing its mission to deliver affordable, high-quality biologics to patients worldwide.

• The contract development and manufacturing services (CDMO) business will operate under a new brand – Rezon Bio – with development and manufacturing activities based at state-of-the-art facilities in Gdańsk and Duchnice near Warsaw.

This step marks a significant milestone in Polpharma Biologics’ evolution, designed to provide sharper strategic focus and operational agility. Both entities will remain rooted in the strong scientific expertise, talent, and innovation that have driven the company’s growth to date.

Konstantin Matentzoglu, CEO of Polpharma Biologics, affirms:

“Our decision to demerge is a natural continuation of our growth journey. By creating two dedicated companies, we can better serve our partners and patients, while unlocking new opportunities for innovation and collaboration. With Polpharma Biologics focused on biosimilars and Rezon Bio dedicated to CDMO services, both businesses are well-positioned to thrive as independent leaders in their respective markets.”

The transformation ensures continuity for partners, employees, and stakeholders, while enabling each business to pursue tailored strategies aligned with their customers’ evolving needs.